MEETING HIGHLIGHTS - 10th ANNIVERSARY INFLAMMATION AND IMMUNE DISEASES DRUG DISCOVERY AND DEVELOPMENT SUMMIT, 20th-21st MARCH 2006, NEW BRUNSWICK, USA

Bibliografía del artículo
1. Park YW, Pryshehep S, Seyler TM el al. B cells as a therapeutic target in autoimmune diseases. Expert Op Ther Targets 2005; 9:431-445.
2. Edwards JCW, Cambridge G. C-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6:394-403.
3. Pescovitz MD. Riruximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6:859-866.
4. Looney RJ. B cell-targeted therapy for rheumatoid arthritis. Drugs 2006; 66:625-639.
5. www.genmab.com.
6. Emery P, Fleischmann R, Fillipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomised, double blind, placebo-controlled, dose-ranging trial. Arthritis & Rheumatism 2006; 54:1390-1400.
7. Cohen SB, Greenwald M, Dougados MR et al. Efficacy and safety of rituximab in active RA patients whoexperienced an inadequate response to one or more anti-TNF therapies (REFLEX study). ACR 2005; abstract 1830.
8. Khobzaoul M, Gutke HJ, Burnet M. CC-10004. Curr Op Invest Drugs 2005; 6:518-525.
9. Molostvov G, Morris A, Rose P et al. The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures. Brit J Haematol 2004; 124:366-375.
10. Gottlieb AB, Malaviya R, Rohane P, Jones M. et al. Biological activity of CC-10004 in patients with severe plaque-type psoriasis. 64th Annual Meeting of the American Academy of Dermatology 2006; p34.
11. Dawson J, Miltz W, Mir AK, Wiessner. Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets 2003; 7:35-48.
12. Murray CM, Hutchinson R, Bantick JR, et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nature Chem Biol 2005; 1:371-376.